Darryl Irwin

Darryl Irwin joined Agena Bioscience in May 2014, having transitioned from Sequenom Inc where he had managed the Asia Pacific Field Applications Support team from August 2006. Darryl is currently Vice President – Scientific Affairs where he leads the global custom assay development group (Assays by Agena) and strategic collaborations initiatives. Prior to Agena, Darryl was the Genotyping Business Unit Manager at the Australian Genome Research Facility, where he managed contract research projects on SNP and microsatellite genotyping technologies. With over 18 years’ experience on the MassARRAY system, Darryl has played a key role in developing novel chemistries and applications as well as mature, robust biomarker panels for disease predisposition, diagnosis, prognosis and monitoring. Darryl previously also held positions in clinical cytogenetics at the Mater Hospitals (Brisbane) and developed an ELISA based diagnostic assay for D-Dimer, a blood clot breakdown product, at Agen Biomedical Inc. Darryl holds a Bachelor of Applied Science from the Queensland University of Technology and a PhD in the area of Non-Invasive Prenatal Testing from the University of Queensland.